Adverum Biotechnologies, Inc. (ADVM)


Stock Price Forecast

May 24, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adverum Biotechnologies, Inc. chart...

About the Company

Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).

Exchange

Nasdaq

$72M

Total Revenue

174

Employees

$152M

Market Capitalization

-5.31

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADVM News

Risks and Returns of Adverum Biotechnologies Inc (ADVM) Stock

4d ago, source: bovnews

H.C. Wainwright raised the price target for the Adverum Biotechnologies Inc (NASDAQ:ADVM) stock to “a Buy”. The rating was released on April 30, 2024, according to finviz. The stock was downgraded by ...

What do you think? Take A Moment To Read: Adverum Biotechnologies Inc (ADVM) Stock

7d ago, source: bovnews

H.C. Wainwright raised the price target for the Adverum Biotechnologies Inc (NASDAQ:ADVM) stock to “a Buy”. The rating was released on April 30, 2024, according to finviz. The stock was downgraded by ...

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

16d ago, source: Business Insider

May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular ...

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

22d ago, source: Yahoo Finance

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for ...

ADVM Adverum Biotechnologies, Inc.

5d ago, source: Seeking Alpha

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a ...

Adverum Biotechnologies, Inc. (ADVM)

23d ago, source: Yahoo Finance

May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular ...

Adverum Biotechnologies Inc ADVM

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adverum Biotechnologies Inc ADVM

10d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adverum Biotechnologies Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...